Eye Inflammation Tied to Anti-Adalimumab Antibody Formation
A study found that over 20% of patients with autoimmune diseases receiving adalimumab developed antibodies against the drug. Ocular inflammation, female sex, and treatment interruptions were linked to a higher risk of antibody formation. The findings highlight the importance of monitoring treatment adherence, especially in at-risk populations.
- ▪Of 704 patients studied, 151 developed antibodies against adalimumab.
- ▪Ocular inflammation was associated with a 67% higher risk for antibody detection.
- ▪Female patients had higher odds of developing anti-adalimumab antibodies compared to male patients.
Medscape files mainly under health. We currently carry 231 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Story provenance
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | Medscape |
| Canonical URL | https://www.medscape.com/viewarticle/eye-inflammation-tied-anti-adalimumab-antibody-formation-2026a1000hwo?src=rss |
| Publication time | Fri, 29 May 2026 03:38:21 EDT |
| Retrieval time | 2026-05-29T07:49:59.659Z |
| Last seen | 2026-05-29T07:49:59.659Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | -IclKBrtKiJr |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
TOPLINE:In patients with autoimmune diseases who received adalimumab, more than one fifth developed antibodies against the drug. The presence of ocular inflammation, female sex, and treatment interruptions were independently associated with an increased risk of developing anti-adalimumab antibodies.METHODOLOGY:Researchers used data from the US-based Stanford Research Repository to conduct a retrospective case-control study of patients who received adalimumab for at least 6 months between June 2005 and May 2024.A total of 704 patients with various autoimmune conditions (mean age, 34.52 years; 50% men) who had at least one documented test for adalimumab drug levels and/or anti-adalimumab antibodies were included in the analysis.The collected data comprised demographics, systemic diagnoses,…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Medscape.
Discussion
0 commentsMore from Medscape
